<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05113784</url>
  </required_header>
  <id_info>
    <org_study_id>MPZ-II-02-CN</org_study_id>
    <nct_id>NCT05113784</nct_id>
  </id_info>
  <brief_title>the Safety and Efficacy of Meplazumab in Patients With COVID-19</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized Controlled, add-on Phase 2/3 Study of the Safety and Efficacy of Meplazumab in Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, double-blind, randomized, placebo-controlled phase 2/3 clinical study.&#xD;
      Based on the results of the Phase I clinical study, one repeat dose group and one placebo&#xD;
      group are used for the standard treatment of the Novel Coronavirus Pneumonia Protocol (Trial&#xD;
      8) The treatment regimen is a one-time intravenous infusion of either mprozumab or placebo on&#xD;
      day 1 (D1) and day 8 (D8) of the treatment period at a dose of 0.2 mg/kg based on body&#xD;
      weight. An estimated 150 subjects will be randomly assigned to either Meplazumab or placebo&#xD;
      in a 2:1 ratio A short-term efficacy evaluation was performed to determine the efficacy and&#xD;
      safety of Meplazumab in each subject within 14 days of initial administration and a long-term&#xD;
      follow-up evaluation was performed 28 days after initial administration to determine the&#xD;
      safety of Meplazumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of virus nucleic acid test turning negative</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Time of virus nucleic acid test turning negative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment to discharge time</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Treatment to discharge time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the imaging parameters</measure>
    <time_frame>up to day28</time_frame>
    <description>Changes from pre-dose baseline in CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the immune response profile</measure>
    <time_frame>up to day28</time_frame>
    <description>Immune response profile characterized according immune cells and subsets and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the biochemistry profile</measure>
    <time_frame>up to day28</time_frame>
    <description>Change from pre-dose baseline in blood biochemistry:Fbg,Cr,BUN,UA,AST,ALT,g-GT,TBIL,ALB,TP,NA,K,Ca,CL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the cytokines profile</measure>
    <time_frame>up to day28</time_frame>
    <description>Change from pre-dose baseline in cytokines:IL-1b、IL-6、IL-8、IL-10、IL-17、CCL2、CXCL-1、CXCL-2、IFN-γ、TNFα、CyPA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Meplazumab for Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First dose: 0.2 mg/kg - Day 1; Second dose: 0.2 mg/kg - Day 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>First dose: control - Day 1; Second dose: control -Day 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meplazumab for Injection</intervention_name>
    <description>humanized antibody target CD147</description>
    <arm_group_label>Meplazumab for Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile normal saline (0.9%)</intervention_name>
    <description>Sterile normal saline (0.9%)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years ≤Subject ≤ 75 years, Male and/or female;&#xD;
&#xD;
          -  Clinical confirmation of COVID-19 patients in accordance with novel Coronavirus&#xD;
             Diagnosis and Treatment Protocol (Trial Version 8) of the NHC&#xD;
&#xD;
          -  Participants must be able to understand and willing to participate in this research,&#xD;
             this study and signed informed consent form (if incapacitated subjects, the&#xD;
             researchers believe the subjects to the test in its own interests, should be signed by&#xD;
             its legal guardian informed consent, or telephone inform consent (recording) and note&#xD;
             it in the original medical records and other relevant documents)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with any unstable conditions, a history of significant hypersensitivity, or&#xD;
             known allergy to components of the investigational agent;&#xD;
&#xD;
          -  SARS-CoV-2 infection by PCR ≥ 96h;&#xD;
&#xD;
          -  Platelet (PLT) &lt; 50×10^9/L, or hemoglobin (HGB) &lt; 60g/L;&#xD;
&#xD;
          -  Total bilirubin (TBIL) &gt; 2×ULN (upper limit of normal value), or alanine transferase&#xD;
             (ALT), aspartate transferase (AST), alkaline phosphatase (ALP) &gt; 5×ULN;&#xD;
&#xD;
          -  glomerular filtration rate (GFR) &lt; 30mL/min·1.73m^2, or serum creatinine increased by&#xD;
             0.5mg/ dL within 7 days, or oliguria (&lt;400mL/24hr), or anuria (&lt;100mL/24hr);&#xD;
&#xD;
          -  Pregnant or breast feeding;&#xD;
&#xD;
          -  Persons who have family planning or do not agree to use effective non-drug&#xD;
             contraceptive measures within 6 months after signing the ICF;&#xD;
&#xD;
          -  Subjects participating in another clinical study. There will be a need for washout&#xD;
             with 5 half lives depending on the study treatment or 30 days since any previous&#xD;
             study, whichever is longer;&#xD;
&#xD;
          -  he inestigators concluded that the patients had other reasons for not being eligible&#xD;
             for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

